Russell Barrans Insider Trading $NEOT Evofem Biosciences, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Russell Barrans.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Russell Barrans. Russell Barrans is Chief Commercial Officer in Evofem Biosciences, Inc. ($NEOT).
Russell Barrans in Evofem Biosciences, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Russell Barrans: Chief Commercial Officer
Holdings: 481,852 shares
Current Value: $819,148
Latest Transaction: Feb 03 2021
$NEOT Market Capitalization: $26.27M
$NEOT Previous Close: $1.70
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Russell Barrans in Evofem Biosciences, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 03 2021 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Option Exercise | A | 3.25 | 150,000 | 487,500 | 150,000 | |
| Feb 03 2021 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Grant | A | 0.00 | 200,000 | 0 | 481,852 | 281.9 K to 481.9 K (+70.96 %) |
| Sep 11 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Buy | P | 2.08 | 3,000 | 6,240 | 279,052 | 276.1 K to 279.1 K (+1.09 %) |
| Sep 11 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Buy | P | 2.71 | 1,000 | 2,710 | 276,052 | 275.1 K to 276.1 K (+0.36 %) |
| Jul 09 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 3.30 | 20,381 | 67,257 | 275,052 | 295.4 K to 275.1 K (-6.90 %) |
| Jun 08 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 3.31 | 15,455 | 51,156 | 293,509 | 309 K to 293.5 K (-5.00 %) |
| May 26 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 4.99 | 19,474 | 97,175 | 308,964 | 328.4 K to 309 K (-5.93 %) |
| May 08 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 5.24 | 3,802 | 19,922 | 328,438 | 332.2 K to 328.4 K (-1.14 %) |
| Feb 21 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Sell | S | 6.50 | 14,957 | 97,221 | 332,240 | 347.2 K to 332.2 K (-4.31 %) |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Option Exercise | A | 4.87 | 100,000 | 487,000 | 100,000 | |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Grant | A | 0.00 | 150,000 | 0 | 347,197 | 197.2 K to 347.2 K (+76.07 %) |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Grant | A | 5.21 | 899 | 4,684 | 197,197 | 196.3 K to 197.2 K (+0.46 %) |
| Jan 21 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Sell | S | 6.50 | 1,578 | 10,257 | 196,298 | 197.9 K to 196.3 K (-0.80 %) |
| Nov 26 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 6.22 | 9,277 | 57,703 | 197,876 | 207.2 K to 197.9 K (-4.48 %) |
| Nov 21 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 5.74 | 9,044 | 51,913 | 207,153 | 216.2 K to 207.2 K (-4.18 %) |
| Aug 26 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 5.13 | 962 | 4,935 | 216,197 | 217.2 K to 216.2 K (-0.44 %) |
| Jul 10 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 4.99 | 13,257 | 66,152 | 217,159 | 230.4 K to 217.2 K (-5.75 %) |
| Jul 10 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Grant | A | 0.00 | 150,000 | 0 | 230,416 | 80.4 K to 230.4 K (+186.53 %) |
| Jul 10 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 4.99 | 13,257 | 66,152 | 217,159 | 230.4 K to 217.2 K (-5.75 %) |
| Jul 10 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Grant | A | 0.00 | 150,000 | 0 | 230,416 | 80.4 K to 230.4 K (+186.53 %) |
| Jun 12 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 6.36 | 5,965 | 37,937 | 80,416 | 86.4 K to 80.4 K (-6.91 %) |
| Apr 03 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 3.55 | 1,160 | 4,118 | 86,381 | 87.5 K to 86.4 K (-1.33 %) |
| Nov 26 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Buy | P | 3.55 | 279 | 990 | 12,820 | 12.5 K to 12.8 K (+2.22 %) |
| Aug 13 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Buy | P | 1.98 | 3,715 | 7,356 | 12,541 | 8.8 K to 12.5 K (+42.09 %) |
| Jul 03 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 2.46 | 2,840 | 6,986 | 8,826 | 11.7 K to 8.8 K (-24.34 %) |
| Jul 03 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Grant | A | 0.00 | 11,666 | 0 | 11,666 | 0 to 11.7 K |
| Mar 14 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Option Exercise | A | 7.29 | 260,000 | 1,895,400 | 260,000 | |
| Jan 18 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Option Exercise | A | 46.36 | 1,283 | 59,480 | 1,283 | |
| Jan 18 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Option Exercise | A | 46.36 | 3,850 | 178,486 | 3,850 |
Page: 1